Skip to content
AnthologyRX

MOTS-c or SS-31?

Mitochondrial research covers very different compounds, populations and outcomes. Here is what belongs to each.

The short answer

MOTS-c’s cited performance research involved dosing mice and observing endogenous peptide changes in exercising humans. SS-31, or elamipretide, has clinical trials and a narrowly defined approved product. Neither establishes a general longevity benefit for the compounded options here.

MOTS-c and SS-31 are not currently offered through AnthologyRX. This comparison remains available for general information.

Side by side

MOTS-c or SS-31?
MOTS-cSS-31 / elamipretide
Research citedAdministered peptide in mice; human exercise observationsTrials in defined mitochondrial diseases
Key distinctionNo human dosing efficacy result in the cited studyDisease-specific findings do not establish general wellness effects
Approval boundaryNot an approved finished medicine hereForzinity approval does not approve compounded SS-31

What the evidence shows

MMPOWER-3 did not meet its primary walking-distance and fatigue endpoints in primary mitochondrial myopathy. FDA’s Forzinity snapshot concerns Barth syndrome and distinguishes the initial randomized findings from strength observations during the open-label extension. Neither is a study of healthy adults seeking more stamina.

Read: Reynolds et al. MOTS-c, exercise and aging; Karaa et al. MMPOWER-3 elamipretide trial; FDA: Forzinity trial snapshot; FDA: Compounding questions and answers.

What matters for your decision

Ask which diagnosis and outcome make the research relevant to you, whether the preparation matches the study and what uncertainty remains. A shared mitochondrial theme is not evidence that the products are substitutes or a beneficial combination.

Questions

Does FDA approval of Forzinity apply to every SS-31 product?

No. Approval belongs to a specific finished product and indication. It does not establish equivalent performance for a compounded preparation.

Sources

  1. Reynolds et al. MOTS-c, exercise and aging

    Nature Communications, 2021. Administered peptide in mice; endogenous peptide observations in humans.

  2. Karaa et al. MMPOWER-3 elamipretide trial

    Neurology, 2023. Primary mitochondrial myopathy; primary walking and fatigue outcomes not met.

  3. FDA: Forzinity trial snapshot

    Elamipretide approval for a specific Barth syndrome population, not general longevity.

  4. FDA: Compounding questions and answers

    The distinction between compounded medications and FDA-approved drug products.

AnthologyRX
Find your treatment
Browse all treatments